

A Multidimensional Model of Fatigue in Patients with Rheumatoid Arthritis

PERRY M. NICASSIO, SARAH R. ORMSETH, MARA K. CUSTODIO, MICHAEL R. IRWIN, RICHARD OLMSTEAD, and MICHAEL H. WEISMAN

ABSTRACT. Objective. To evaluate a multidimensional model testing disease activity, mood disturbance, and poor sleep quality as determinants of fatigue in patients with rheumatoid arthritis (RA).

Method. The data of 106 participants were drawn from baseline of a randomized comparative efficacy trial of psychosocial interventions for RA. Sets of reliable and valid measures were used to represent model constructs. Structural equation modeling was used to test the direct effects of disease activity, mood disturbance, and poor sleep quality on fatigue, as well as the indirect effects of disease activity as mediated by mood disturbance and poor sleep quality.

Results. The final model fit the data well, and the specified predictors explained 62% of the variance in fatigue. Higher levels of disease activity, mood disturbance, and poor sleep quality had direct effects on fatigue. Disease activity was indirectly related to fatigue through its effects on mood disturbance, which in turn was related to poor sleep quality. Mood disturbance also indirectly influenced fatigue through poor sleep quality.

Conclusion. Our findings confirmed the importance of a multidimensional framework in evaluating the contribution of disease activity, mood disturbance, and sleep quality to fatigue in RA using a structural equation approach. Mood disturbance and poor sleep quality played major roles in explaining fatigue along with patient-reported disease activity. (First Release June 1 2012; J Rheumatol 2012;39:1807–13; doi:10.3899/jrheum.111068)

Key Indexing Terms:

RHEUMATOID ARTHRITIS
SLEEP DISORDERS

FATIGUE

MOOD
PSYCHOLOGICAL FACTORS

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint pain, stiffness, and inflammation of joint synovial tissue^{1,2}. While fatigue is not required for a diagnosis of RA, persistent fatigue is a problem for > 50% of patients with RA^{3,4}. In many instances, fatigue may contribute to work disability and interfere with role functioning, thus adding significantly to patients' disease burden^{5,6}. Despite the

prevalence and effect of fatigue, research on the use of biologic agents and disease-modifying drugs in the treatment of fatigue is limited and inconclusive⁷. Because of ambiguities in the etiology and treatment of fatigue, the management of fatigue in clinical practice is a challenge to clinicians and patients alike.

The identification of factors that contribute to RA fatigue may lead to enhanced approaches to treatment and management. Disease activity and excessive inflammation have been postulated to contribute significantly to fatigue in RA⁸. Pain and fatigue in RA tend to be positively correlated^{9,10}, leading researchers to conclude that fatigue may be the product of the inflammatory response or a secondary response to other disease characteristics⁸. However, studies analyzing the association between disease activity and fatigue in RA have not demonstrated that inflammation is an important explanatory factor in fatigue^{9,11,12,13,14}. For example, Bergman, *et al*¹³ found weak associations between fatigue and erythrocyte sedimentation rate (ESR), tender and swollen joints, and the 28-joint Disease Activity Score (DAS28), and a much stronger correlation between patients' global health rating and fatigue in a cohort of 2096 patients with RA. Using a multivariate approach, Riemsma, *et al*⁹ found that pain, low efficacy expectations, and problematic support explained 37% of the variance in fatigue, while ESR, rheumatoid factor, and hemoglobin did not contribute to fatigue. In a more recent

From the Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA); Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles; and Loma Linda University, Loma Linda, California, USA.

Supported by AR R01-049840 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (P.M. Nicassio). Also supported in part by T32-MH19925, HL 079955, AG034588, AG026364, CA119159, DA 027558, RR00827, P30-AG028748, General Clinical Research Centers Program, the UCLA Cousins Center at the Semel Institute for Neurosciences, and the UCLA Older Americans Independence Center Inflammatory Biology Core.

P.M. Nicassio, PhD; M.K. Custodio, BA; M.R. Irwin, MD; R. Olmstead, PhD, Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA; S.R. Ormseth, MA, Department of Psychology, Loma Linda University; M.H. Weisman, MD, Division of Rheumatology, Cedars Sinai Medical Center.

Address correspondence to Dr. P.M. Nicassio, 300 UCLA Medical Plaza, Los Angeles, CA 90095-7076, USA. E-mail: pnicassio@mednet.ucla.edu
Accepted for publication March 23, 2012.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2012. All rights reserved.

study finding similar results, van Hoogmoed, *et al*¹⁴ reported that pain, disability, depression, and low self-efficacy were associated with greater fatigue, but that inflammatory indices were not correlated with fatigue severity.

In view of these conflicting results, a multidimensional approach, incorporating psychosocial factors, may be warranted in analyzing the factors that contribute to fatigue in RA. In addition to pain and fatigue, many patients with RA have problems with mood and sleep. For example, between 20% and 30% of patients experience significant depressive symptoms or may have a mood disorder¹⁵, while > 50% report problems with sleep continuity, insomnia, and poor sleep quality¹⁶. Poor sleep may result from depression, and depression and poor sleep may jointly contribute to fatigue in RA¹⁷. Thus, fatigue may be the product of RA disease activity, along with depression and poor sleep. It is also possible that disease activity may affect fatigue indirectly, by leading to mood disturbance and/or sleeping difficulties. Therefore it is possible that depression and poor sleep quality may be potential mechanisms through which disease activity contributes to fatigue. These mechanisms could then be targeted for the management of fatigue in RA. Current research, however, has not addressed the direct and indirect contributions of disease activity to fatigue through these mechanisms. Thus, questions regarding the etiology of fatigue in RA are largely unresolved.

The major purpose of this research was to examine a model describing the interrelations among disease activity, mood disturbance, and poor sleep quality as determinants of fatigue in an urban sample of patients with RA. Structural equation modeling was adopted to illustrate the complexity of relations among variables in the proposed model (Figure 1). It was hypothesized that disease activity would be positively associated with fatigue directly and/or indirectly through the potential mediators of mood disturbance and poor sleep quality. Specifically, the model proposed that higher levels of disease activity would lead to greater mood disturbance, which in turn would contribute to poor sleep quality. Further, higher levels of disease activity and poor sleep quality were expected to contribute to greater fatigue. Finally, it was also hypothesized that the effect of disease activity on fatigue would, at least in part, be indirect, through its effects on mood disturbance and sleep quality.




Figure 1. Hypothesized direct and indirect effects of disease activity, mood disturbance, and poor sleep quality on fatigue.

MATERIALS AND METHODS

Patient sample. Participants were recruited through flyers posted in clinics in the Divisions of Rheumatology at Cedars Sinai Medical Center (CSMC) and the University of California, Los Angeles (UCLA), and through advertisements in local newspapers, announcing a treatment outcome study designed to help patients manage RA. Patients were referred to CSMC to determine medical eligibility after they had passed a telephone screening. After obtaining informed consent to participate in the project, the study rheumatologist (MW) at CSMC conducted a diagnostic evaluation to verify the RA diagnosis. Participants had to (1) be 18 years of age or older; (2) fulfill the American College of Rheumatology revised criteria for RA; (3) have a stable disease-modifying drug regimen for 3 months prior to study entry; (4) have a stable disease course for 3 months; (5) be free of serious comorbid medical conditions such as diabetes, congestive heart failure, renal failure, cancer, or fibromyalgia, which would confound interpretations of health status; and (6) not be pregnant.

At UCLA, eligible patients gave a second informed consent to participate in an evaluation of psychiatric status, physical functioning, and psychosocial adjustment. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders¹⁸ was administered, and psychiatric diagnoses were made in a consensus meeting with the principal investigator (PN) and project psychiatrist (MI). Patients who had a serious psychiatric condition such as bipolar disorder, psychosis, or posttraumatic stress disorder, or who were at risk for suicide, were ineligible to participate. Because none of the patients had any of those conditions, no patients were excluded after the diagnostic evaluation.

Data collection. This research reports on baseline data collected from all eligible participants who qualified for a treatment outcome study examining the efficacy of behavioral interventions for RA. At baseline, the psychosocial functioning and disease activity of participants were evaluated. The psychosocial component of the evaluation included self-report assessments of disease activity, mood disturbance, sleep, and fatigue, which are the focus of this report. In addition, reports of medication use were obtained, including analgesics/nonsteroidal antiinflammatory drugs, biologic agents, disease-modifying antirheumatic drugs (DMARD), and “other” (drugs for other medical conditions, including psychotropic agents).

Measures. The structural model tested in our study (Figure 1) was composed of the constructs of disease activity, mood disturbance, poor sleep quality, and fatigue. Multiple reliable and valid measures were used to serve as indicators in the model to increase the reliability of each construct.

The latent variable, disease activity, included 2 indicators representing joint pain/tenderness and RA disease activity as measured in the Rapid Assessment of Disease Activity in Rheumatology scale (RADAR)¹⁹. The RADAR joint pain/tenderness assesses degree of pain/tenderness in 10 joints on the right and left sides of the body. Items are rated on a 4-point Likert scale; the sum score may range from 0 to 60, with higher scores indicating more severe joint pain/tenderness. For self-perceived RA disease activity, respondents rated “How active has your arthritis been over the past 6 months?” and “How active is your arthritis today?” on 10-point visual analog scales, higher scores indicating greater perceived disease activity. Scores on the 2 scales were totaled to create a single disease activity variable. The RADAR has been shown to be an efficient, valid proxy for physician assessments of disease activity and joint pain²⁰.

Mood disturbance was included as a latent variable with 2 indicators representing the Center for Epidemiological Studies Depression Scale (CES-D)²¹ and the Perceived Stress Scale (PSS)²². The CES-D consists of 20 items and was designed to assess the existence of depressive symptomatology in community samples and nonpsychiatric groups. Scores may range from 0 to 60, with higher scores signifying the presence of more symptomatology. The PSS, comprising 10 items, measures the degree to which participants find their lives to be unpredictable, uncontrollable, and overwhelming. The PSS assesses the cognitive and emotional burden of feeling stressed rather than events that may lead to stress. Scores may range from 0 to 40, higher scores indicating greater perceived stress.

The Pittsburgh Sleep Quality Index (PSQI)²³ measured patients' sleep quality. The PSQI is a 19-item scale that has demonstrated strong internal consistency and diagnostic validity in the evaluation of self-reported sleep disturbance. Seven sleep component scores are derived and each may range from 0 (no difficulty) to 3 (severe difficulty). Three indicators of the latent variable poor sleep quality were adopted, representing PSQI component scores²⁴: (1) sleep efficiency, the sum of sleep duration and habitual sleep efficacy subscales; (2) perceived sleep quality, the sum of subjective sleep quality, sleep latency, and sleeping medication use subscales; and (3) daily disturbances, the sum of sleep disturbances and daytime dysfunction subscales.

Two indicators were used to measure the latent variable, fatigue: the Multidimensional Assessment of Fatigue (MAF) Global Fatigue Index²⁵ and the Vitality Subscale of the Medical Outcomes Study Short Form-36 (SF-36)²⁶ questionnaire. The MAF consists of 16 items measuring severity and effect of fatigue and has been used in RA research²⁴. Scores may range from 1 to 50, higher scores representing more severe fatigue. The SF-36 Vitality Subscale is a 4-item subscale with 2 positively worded items ("Did you feel full of pep?" and "Did you have a lot of energy?") and 2 negatively worded items ("Did you feel worn out?" and "Did you feel tired?"). Scores may range from 0 to 100, higher scores indicating higher levels of vitality.

Statistical analyses. Structural equation modeling was used to test the hypotheses exploring the proposed relations among disease activity, mood disturbance, sleep quality, and fatigue. The hypothesized model was tested using Bentler's structural equations program (EQS 6.1) with the maximum likelihood method of estimation²⁷. The model was assessed using multiple fit criteria: chi-squared goodness-of-fit statistic, the ratio of chi-squared to the degrees of freedom (chi-squared/df), the Comparative Fit Index (CFI), the standardized root mean residual (SRMR), and the root mean square error of approximation (RMSEA). A statistically nonsignificant chi-squared ($p > 0.05$) is suggestive of a good match between the data and the hypothesized model. Additionally, a ratio of chi-squared to degrees of freedom value < 2 (chi-square/df < 2) is considered another indicator of good model fit. A CFI value > 0.90 is considered evidence of a good-fitting model²⁸. For SRMR and RMSEA, the joint criteria of an SRMR < 0.09 and an RMSEA < 0.06 is considered optimal to minimize the rates of type I and type II error²⁹. Model modifications were performed based on results from the Wald test and the Lagrange multiplier (LM) test, along with theoretical considerations.

Covariates. The associations between medication use (i.e., analgesics/non-steroidal antiinflammatory drugs, biologic agents, DMARD, and other medications) and the indicator variables of sleep disturbance and fatigue were also assessed to determine their potential effect on model findings. If statistically significant, relevant covariates would have been partitioned from the indicators of the noted outcomes prior to SEM analyses.

RESULTS

Sample characteristics. A total of 106 patients were included in our study. Table 1 shows demographic characteristics of the sample. There were 88 women and 18 men, with an average age of 56.09 years and illness duration of 11.23 years. Participants came from a range of ethnicities. Whites were the most prevalent group, but African American, Hispanic, and Asian ethnicities were also represented. The sample can be characterized as middle to upper middle class, possessing almost 16 years of education on average, and a median household income $> \$50,000$ per year.

SEM results. Prior to testing the model, the data were screened, and results revealed a normal distribution and no multivariate outliers. Further, in the assessment of covariates, none of the associations between medication use and the indicator variables of sleep disturbance and fatigue were found to be statistically significant (Correlations among model vari-

Table 1. Demographic characteristics of study sample (n = 106).

Characteristics	N (%)
Sex	
Male	18 (16.98)
Female	88 (83.02)
Race/ethnicity	
White	56 (53.83)
Hispanic	16 (15.09)
Black	11 (10.38)
Asian/Pacific Islander	8 (7.54)
Other race/ethnicity	15 (14.15)
Marital status	
Married	46 (43.40)
Divorced/separated	26 (24.53)
Widowed	9 (8.49)
Single	13 (12.26)
Other/unknown	12 (11.32)
Age, yrs, mean (SD)	56.09 (12.45)
Yearly median income (\$) by postal code, mean (SD)	50,850 (22,525)
Education, yrs, mean (SD)	15.95 (2.40)
Years since RA diagnosis, mean (SD)	10.75 (11.23)

ables are given in Table 2). The hypothesized model provided a good fit to the data: CFI = 0.997; chi-squared²¹ = 22.29, $p = 0.383$; chi-squared/df = 1.06; SRMR = 0.039; and RMSEA = 0.024. However, the Wald test indicated that the effect of deleting the path from disease activity to sleep disturbance on the chi-square of the model would be minimal. Therefore, based on theoretical plausibility, and in an effort to simplify the model, this path was removed. The fit of this revised model was similar: CFI = 0.999; chi-squared²² = 22.45, $p = 0.433$; chi-squared/df = 1.02; SRMR = 0.040; RMSEA = 0.014, and the model now consisted of only statistically significant paths ($p < 0.05$; Table 3). The Wald test and the LM test did not indicate any further improvement of the model through the deletion or addition of paths. Overall, the specified predictors explained 19% of the variance in mood disturbance, 22% of the variance in sleep quality, and 62% of the variance in fatigue.

Test of research hypotheses. Inspection of the path coefficients showed that the hypothesized relations among model constructs were generally confirmed (Table 3). As expected, disease activity exerted a positive influence on mood disturbance ($\beta = 0.44$, $p < 0.001$), and higher levels of mood disturbance predicted poorer sleep quality ($\beta = 0.47$, $p < 0.001$). In turn, poor sleep quality exerted a strong, positive, direct effect on fatigue ($\beta = 0.41$, $p < 0.001$). Further, disease activity directly and positively predicted fatigue ($\beta = 0.29$, $p = .005$). Disease activity was also positively, indirectly related to fatigue through mood disturbance and poor sleep quality ($\beta_{\text{indirect}} = 0.23$, $p = 0.003$). In addition, mood disturbance directly and indirectly influenced fatigue through poor sleep quality ($\beta = 0.34$, $p = 0.005$, and $\beta_{\text{indirect}} = 0.19$, $p = 0.002$, respectively). The final model with standardized path coefficients is shown in Figure 2.

Table 2. Intercorrelations, means, and SD for study variables (n = 106).

Variables	1	2	3	4	5	6	7	8	9
1. RADAR total joint	—								
2. RADAR disease activity	0.617***	—							
3. CES-D total	0.307***	0.332***	—						
4. Perceived stress scale total	0.273***	0.295***	0.645***	—					
5. PSQI sleep efficiency	0.064	0.069	0.152	0.135	—				
6. PSQI sleep quality	0.139	0.150	0.329***	0.292***	0.297***	—			
7. PSQI daily disturbances	0.165*	0.178*	0.390***	0.347***	0.352***	0.762***	—		
8. SF-36 vitality subscale	-0.381***	-0.411***	-0.357***	-0.318***	-0.212**	-0.459***	-0.544***	—	
9. MAF global fatigue index	0.372***	0.401***	0.349***	0.310***	0.207**	0.447***	0.531***	-0.787***	—
Mean (SD)	11.45 (9.34)	10.60 (6.93)	8.87 (9.17)	11.35 (6.90)	1.43 (1.43)	2.43 (2.04)	1.71 (1.29)	53.73 (23.71)	21.03 (10.56)

* p < 0.05; ** p < 0.01; *** p < 0.001. RADAR: Rapid Assessment of Disease Activity in Rheumatology; CES-D: Center for Epidemiological Studies depression scale; PSQI: Pittsburgh Sleep Quality Index; MAF: Multidimensional Assessment of Fatigue; SF-36: Medical Outcomes Study Short Form-36 questionnaire.

Table 3. Path coefficients from the final revised structural equation model.

	Unstandardized	SE	Standardized
Direct effects			
Disease activity → Mood disturbance	3.355***	0.933	0.437
Disease activity → Fatigue	2.595**	0.913	0.285
Mood disturbance → Poor sleep quality	0.076***	0.018	0.469
Mood disturbance → Fatigue	0.402**	0.143	0.338
Poor sleep quality → Fatigue	3.004***	0.754	0.408
Indirect effects			
Disease activity → Poor sleep quality	0.254**	0.087	0.205
Disease activity → Fatigue	2.110**	0.698	0.231
Mood disturbance → Fatigue	0.227**	0.073	0.191

** p < 0.01; *** p < 0.001.




Figure 2. Final model with estimated path coefficients and factor loadings. RADAR Joint Total: Rapid Assessment of Disease Activity in Rheumatology Joint Total score; RADAR Disease Act.: RADAR Disease Activity score; CES-D: Center for Epidemiological Studies Depression scale; PSS: Perceived Stress Scale; PSQI F1: Pittsburgh Sleep Quality Index sleep efficiency factor; PSQI F2: PSQI perceived sleep quality factor; PSQI F3: PSQI daily disturbances factor; MAF Global Fatigue: Multidimensional Assessment of Fatigue Global Fatigue index; SF-36 Vitality: Medical Outcomes Study Short Form-36 questionnaire Vitality Subscale. *p < 0.01. **p < 0.001.

DISCUSSION

The causes of fatigue in RA are difficult to interpret in clinical practice. While RA fatigue has been viewed as the byproduct of the inflammatory response and heightened disease activity, previous research has shown that disease activity is inconsistently related to fatigue, and that psychosocial factors may play a crucial role in this symptom^{13,14}. Accordingly, the goal of our research was to evaluate a multidimensional model, based on the assumption that several factors may contribute to fatigue in RA. A structural equation modeling approach was adopted to illustrate both direct and indirect mechanisms through which disease activity could potentially contribute to fatigue in an urban sample of patients with RA. Specifically, we examined whether RA disease activity would contribute to fatigue through mood disturbance and poor sleep quality.

The initial model examined the hypothesis that disease activity would contribute to mood disturbance and poor sleep quality, which in turn would contribute to higher fatigue. The path from mood disturbance to poor sleep quality was also examined. While this model had very good fit, because the path from disease activity to poor sleep quality was not significant, an alternative model was examined that eliminated this path. This alternative model had slightly better fit and served as a more restrained explanation of the data. The final model revealed a significant, indirect path from disease activity to mood disturbance, from mood disturbance to poor sleep quality, and from poor sleep quality to fatigue. Both disease activity and mood disturbance retained direct relationships with fatigue.

Our findings extend the work of previous research showing that pain and depression are both related to RA fatigue^{6,10}, and that patients who have a history of an affective disorder have more fatigue with RA than patients who do not³⁰. Importantly, the data also revealed that RADAR scores, comprising both joint pain and reports of disease activity, were related to fatigue through mood disturbance, which in our study was measured by depression and perceived stress. Mood disturbance thus may serve as an important pathway through which disease activity exacerbates fatigue. Other research has shown a significant relationship between RA disease activity and depression³¹, but our study has provided a new perspective on how these variables may act conjointly to affect fatigue.

The model also found that poor sleep quality was related to fatigue. Previous research has found a high prevalence of sleep disturbance in RA¹⁶, and that both pain and depression may contribute to poor sleep¹⁷. Using daily diary data, Goodchild, *et al*³² found that the previous night's discomfort was associated with lower sleep efficiency and poorer sleep quality in RA. Our results demonstrated that while mood disturbance contributed significantly to poor sleep quality, disease activity was related to poor sleep quality only through mood disturbance. Thus, coupled with the findings above, mood disturbance was an important mediational variable

through which disease activity contributed to both poor sleep and fatigue.

Our findings suggest that fatigue in RA may have multiple determinants. Previous studies, using multidimensional models, have also documented the importance of such variables as pain, mood, and coping processes in explaining RA fatigue^{9,14}. Importantly, the findings of this research illustrate the significance of conceptualizing the links between disease activity and functional outcomes in RA. A possible reason for the inconsistent relationship between disease activity and fatigue in RA in previous studies may be that the indirect relationships between disease activity, psychological factors, and fatigue had not been analyzed. Importantly, this research has shown that the contribution of disease activity to fatigue is largely explained by mechanisms underlying mood disturbance and poor sleep. Our findings also have clinical relevance, suggesting that treatments that focus on better mood regulation and sleep may contribute to improvement in patients' fatigue and vitality. Findings reported by Hewlett, *et al*³³ and Evers, *et al*³⁴ indicate that cognitive-behavior therapy may promote improvement in fatigue and mood in patients with RA. Thus, successful treatment for RA disease activity may not lead to reduced fatigue unless problems in mood and sleep are adequately addressed.

It is important to note that, while all measures in the study had demonstrated validity, the use of self-report may have contributed in some degree to the magnitude of the relationships that were observed among constructs. The report of poor sleep or short sleep duration may reflect the existence of anxious-ruminative traits or inadequate resources for managing stress^{35,36}. The PSQI, for example, has been shown to be more closely related to depression and psychological distress than to polysomnographic abnormalities^{37,38}. While the PSQI is one of the best-established and widely used self-report measures of sleep quality, other instruments may also be appropriate for measuring sleep quality in RA and should be considered in future research³⁹. The measurement of the perception of sleep health in medical populations remains an important challenge because of the difficulty in separating illness-related symptoms from those associated with reports of sleep quality.

Despite the excellent fit of the model that we examined, the study possessed some limitations that warrant a cautious interpretation of the results. First, because the findings from this research were based on an urban RA sample recruited to participate in psychosocial research, they may not be generalizable to other patient populations such as those residing in rural areas or those out of the mainstream of clinical care. Second, while the findings are consistent with the model that was hypothesized, the cross-sectional design precluded an interpretation of causality or directionality among variables. The structural equation model that was examined was based only on hypothesized relationships between the variables chosen. Nonrecursive, synergistic relationships may exist between variables that were examined, leading to the consideration of

other plausible models linking disease activity with fatigue. Poor sleep, for example, may contribute to both mood disturbance and pain⁴⁰, which in turn may lead to greater fatigue. Longitudinal research and studies adopting daily assessment procedures that identify the ebb and flow of RA disease activity, mood disturbance, sleep, and fatigue⁴¹ would clarify the directional and mediational mechanisms that we examined.

ACKNOWLEDGMENT

The authors wish to acknowledge Kate Jackson, BA, and Sarosh J. Motivala, PhD, who contributed to the diagnostic evaluation and assessment of participants in the project.

REFERENCES

1. Wolfe F, Cathey M. The assessment and prediction of functional disability in rheumatoid arthritis. *J Rheumatol* 1991;18:1298-306.
2. Escalante A, Del Rincón I. The disablement process in rheumatoid arthritis. *Arthritis Rheum* 2002;47:333-42.
3. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. *J Rheumatol* 1996;23:1407-17.
4. Tack BB. Self-reported fatigue in rheumatoid arthritis: A pilot study. *Arthritis Care Res* 1990;3:154-7.
5. Belza BL, Henke CJ, Yelin EH, Epstein WV, Gilliss CL. Correlates of fatigue in older adults with rheumatoid arthritis. *Nurs Res* 1993;42:93-9.
6. Mancuso CA, Paget SA, Charlson ME. Adaptations made by rheumatoid arthritis patients to continue working: A pilot study of workplace challenges and successful adaptations. *Arthritis Care Res* 2000;13:89-99.
7. Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: A systematic review of the literature and meta-analysis. *Rheumatology* 2012;51:60-8.
8. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. *Arthritis Rheum* 2008;59:1371-7.
9. Riemsma RP, Rasker JJ, Taal E, Griep EN, Wouters JM, Wiegman O. Fatigue in rheumatoid arthritis: The role of self-efficacy and problematic social support. *Br J Rheumatol* 1998;37:1042-6.
10. Wolfe F. Determinants of WOMAC function, pain and stiffness scores: Evidence for the role of low back pain, symptom counts, fatigue and depression in osteoarthritis, rheumatoid arthritis and fibromyalgia. *Rheumatology* 1999;38:355-61.
11. Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in rheumatoid arthritis reflects pain, not disease activity. *Rheumatology* 2006;45:885-9.
12. Repping-Wuts H, Fransen J, van Achterberg T, Bleijenberg G, van Riel P. Persistent severe fatigue in patients with rheumatoid arthritis. *J Clin Nurs* 2007;16:377-83.
13. Bergman MJ, Shahouri SS, Shaver TS, Anderson JD, Weidensaul DN, Busch RE, et al. Is fatigue an inflammatory variable in rheumatoid arthritis (RA)? Analyses of fatigue in RA, osteoarthritis, and fibromyalgia. *J Rheumatol* 2009;36:2788-94.
14. van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. *Rheumatology* 2010;49:1294-302.
15. Covic T, Tyson G, Spencer D, Howe G. Depression in rheumatoid arthritis patients: Demographic, clinical, and psychological predictors. *J Psychosom Res* 2006;60:469-76.
16. Abad VC, Sarinas PS, Guilleminault C. Sleep and rheumatologic disorders. *Sleep Med Rev* 2008;12:211-28.
17. Wolfe F, Michaud K, Li T. Sleep disturbance in patients with rheumatoid arthritis: Evaluation by Medical Outcomes Study and visual analog sleep scales. *J Rheumatol* 2006;33:1942-51.
18. Spitzer RL, Williams JBW, Gibbon M. Structured clinical interview for DSM-III-R (SCID). New York: Biometrics Research; 1987.
19. Wong AL, Wong WK, Harker J, Sterz M, Bulpitt K, Park G, et al. Patient self-report tender and swollen joint counts in early rheumatoid arthritis. *J Rheumatol* 1999;26:2551-61.
20. Calvo FA, Calvo A, Berrocal A, Pevez C, Romero F, Vega E, et al. Self-administered joint counts in rheumatoid arthritis: Comparison with standard joint counts. *J Rheumatol* 1999;26:536-9.
21. Radloff L. The CES-D Scale: A self-report depression scale for research in general populations. *Appl Psychol Meas* 1977;1:385-401.
22. Cohen AS, Williamson GM. Perceived stress in a probability sample of the United States. In: Scapapan S, Oskamp S, editors. *The social psychology of health*. 4th ed. Newbury Park, CA: Sage Publications; 1988:31-67.
23. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. *Psychiatry Res* 1989;28:193-213.
24. Cole JC, Motivala SJ, Buysse DJ, Oxman MN, Levin MJ, Irwin MR. Validation of a 3-factor scoring model for the Pittsburgh Sleep Quality Index in older adults. *Sleep* 2006;29:112-6.
25. Belza BL. Comparison of self-reported fatigue in rheumatoid arthritis and controls. *J Rheumatol* 1995;22:639-43.
26. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30:473-83.
27. Bentler PM. EQS 6 structural equations program manual. Encino, CA: Multivariate Software; 2005.
28. Bentler PM, Bonett DG. Significance tests and goodness of fit in the analysis of covariance structures. *Psychol Bull* 1980;88:588-606.
29. Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. *Struct Equ Modeling* 1999;16:1-55.
30. Jump FL, Fifield J, Tennen H, Reisine S, Giuliano AJ. History of affective disorder and the experience of fatigue in rheumatoid arthritis. *Arthritis Care Res* 2004;51:239-45.
31. Godha D, Shi L, Mavronicolas H. Association between tendency towards depression and severity of rheumatoid arthritis from a national representative sample: The Medical Expenditure Panel Survey. *Curr Med Res Opin* 2010;26:1685-90.
32. Goodchild CE, Treharne GJ, Booth DA, Bowman SJ. Daytime patterning of fatigue and its associations with the previous night's discomfort and poor sleep among women with primary Sjogren's syndrome or rheumatoid arthritis. *Musculoskeletal Care* 2010;9:107-17.
33. Hewlett S, Ambler N, Almeida C, Cliss A, Hammond A, Kitchen K, et al. Self-management of fatigue in rheumatoid arthritis: A randomised controlled trial of group cognitive-behavioural therapy. *Ann Rheum Dis* 2011;70:1060-7.
34. Evers AW, Kraaijmaat FW, van Riel PL, de Jong AJ. Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: A randomized controlled trial. *Pain* 2002;100:141-53.
35. Fernandez-Mendoza J, Calhoun SL, Bixler EO, Karataraki M, Liao D, Vela-Bueno A, et al. Sleep misperception and chronic insomnia in the general population: Role of objective sleep duration and psychological profiles. *Psychosom Med* 2011;73:88-97.
36. Venable PA, Aikens JE, Tadimeti L, Caruana-Montaldo B, Mendelson WB. Sleep latency and duration estimates among sleep disorder patients: Variability as a function of sleep disorder diagnosis, sleep history, and psychological characteristics. *Sleep* 2000;23:71-9.

37. Buysse DJ, Hall ML, Strollo PJ, Kamarck TW, Owens J, Lee L, et al. Relationships between the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and clinical/polysomnographic measures in a community sample. *J Clin Sleep Med* 2008;4:563-71.
38. Taylor-Gjevre RM, Gjevre JA, Nair B, Skomro R, Lim HJ. Components of sleep quality and sleep fragmentation in rheumatoid arthritis and osteoarthritis. *Musculoskeletal Care* 2011 June 5. (E-pub ahead of print).
39. Wells GA, Li T, Kirwin JR, Peterson J, Aletaha D, Boers M, et al. Assessing quality of sleep in patients with rheumatoid arthritis. *J Rheumatol* 2009;36:2077-86.
40. Luyster FS, Chasens ER, Wasko MC, Dunbar-Jacob J. Sleep quality and functional disability in patients with rheumatoid arthritis. *J Clin Sleep Med* 2011;7:49-55.
41. Broderick JE, Schwartz JE, Schneider S, Stone AA. Can end-of-day reports replace momentary assessment of pain and fatigue? *J Pain* 2009;10:274-81.